Monte Rosa Therapeutics Inc (GLUE)
Healthcare
Biotechnology
—
16.50 $
-27.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Monte Rosa Therapeutics Inc (GLUE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -37 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25 | -25 | 30 | -38 | -28 | -21 | 129 | -45 | -35 | 100 | -43 | -37 | -15 | |
| 1.4 | 1.8 | 1.8 | 1.9 | 2.1 | 2.1 | 2.1 | 2.0 | 2.1 | 2.1 | 2.1 | 2.0 | 8.3 | |
| 4.2 | 4.5 | 4.1 | 4.9 | 4.5 | 4.3 | 4.5 | 5.3 | 4.9 | 4.4 | 4.3 | 5.9 | 20 | |
| 2.7 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 5.7 | 4.4 | 58 | -13 | -2.9 | -2.4 | 110 | -99 | -29 | 122 | -3.4 | 0.1 | 90 | |
| 6.5 | 1.7 | 1.7 | 1.4 | 2.0 | 0.4 | 0.2 | 1.6 | 1.7 | 0.7 | 0.8 | 1.9 | 5.0 | |
| 19 | 36 | 14 | 9.9 | -61 | 38 | -31 | -100 | 25 | 38 | -65 | -261 | -263 | |
| – | – | – | – | – | – | 0.0 | – | – | – | -0.4 | – | – | |
| 1.2 | 1.1 | 25 | 0.2 | 98 | 0.0 | 0.6 | 0.0 | 0.4 | 0.3 | 30 | 328 | 359 | |
| -5.8 | 12 | 69 | -28 | 9.1 | 17 | 99 | -146 | -9.0 | 139 | -78 | 30 | 81 | |
| -32 | -26 | 28 | -40 | -30 | -21 | 129 | -47 | -36 | 100 | -44 | -39 | -20 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.